NDC 0469-7271-01 - Cefizox
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0469-7271
- Requested NDC
- 0469-7271-01
- Package NDCs from labels
- 0469-7271-01
- Manufacturer
- Fujisawa Healthcare, Inc.
- Effective date
- 2006-06-08
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cefizox® (CEFTIZOXIME FOR INJECTION, USP) | Fujisawa Healthcare, Inc. | 2006-06-08 | Human prescription drug label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0469-7271-01 | Cefizox | 1 in 1 VIAL | INJECTION, POWDER, LYOPHILIZED, | 1 | 1 | |
| 0469-7271-01 | Cefizox | 10 in 1 PACKAGE | INJECTION, POWDER, LYOPHILIZED, | 10 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| ceftizoxime sodium | ACTIVE INGREDIENT | 26337D5X88 | CEFIZOX (CEFTIZOXIME) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FUJISAWA HEALTHCARE, INC.] | 1 | |
| ceftizoxime | ACTIVE MOIETY | C43C467DPE | CEFIZOX (CEFTIZOXIME) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [FUJISAWA HEALTHCARE, INC.] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 0013824B-6AEE-4DA4-AFFD-35BC6BF19D91 | 0013824B-6AEE-4DA4-AFFD-35BC6BF19D91 | 2006-06-08 | Warnings, Adverse reactions | 0013824B-6AEE-4DA4-AFFD-35BC6BF19D91 0013824B-6AEE-4DA4-AFFD-35BC6BF19D91 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.